The present invention relates to pharmaceutical combinations of peroxisome proliferator-activated receptor (PPAR) agonist(s) with sterol absorption inhibitor(s), as well as to the use of these combinations for treating and/or preventing non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (...

The invention relates to an extended release oral pharmaceutical composition comprising upadacitinib or its pharmaceutically acceptable salts thereof, a hydrophobic release controlling agent and optionally one or more pharmaceutically acceptable excipients. The present invention further relates to a process for ...

ABSTRACT PROCESS FOR THE PREPARATION OF REMOGLIFLOZIN, IT’S INTERMEDIATES, ETABONATE SALT AND PURIFICATION THEREOF The present invention provides a process for the preparation of Remogliflozin etabonate and intermediates thereof. The present invention further relates to process of purification of Remoglifl...

ABSTRACT The present invention relates to a packaging laminate and process for preparation thereof, wherein said packaging laminate is easy to tear, has excellent barrier properties, and mechanically strong enough for convenient handling. Dated this, 9th day of September, 2022 For Mankind Pharma Ltd....

ABSTRACT The present invention relates to a stable ophthalmic composition comprising loteprednol or its pharmaceutically acceptable salt thereof, one or more suspending agents, and optionally one or more excipients. Dated this the 13th day of May 2022. For Mankind Pharma Ltd. ...

NOVEL PROCESS FOR THE PREPARATION OF CISATRACURIUM OR ITS SALT THEREOF ABSTRACT The present invention relates to process of preparation of Cisatracurim or its salt of Formula IIa by involving use of novel compound of Formula I . where X- is an anion selected from chloride, bromide, iodide, tetrafluor...

PROCESS FOR THE PREPARATION OF HALOPERIDOL, ITS INTERMEDIATES, SALT AND PURIFICATION THEREOF ABSTRACT Present invention provides a process for the preparation of Haloperidol of Formula I, its intermediates, salt and purification thereof, Formula I Present invention further pr...

The present invention relates to liquid dispensing container made of material comprising a matrix in which antimicrobial beads are dispersed and evenly distributed throughout the container, wherein said beads have an antimicrobial effect and wherein said containers are configured to store preservative free thera...

ABSTRACT The present invention relates to a topical pharmaceutical composition comprising dydrogesterone, and one or more pharmaceutically acceptable excipients. Moreover, the present invention also relates to the process for the preparation of the topical pharmaceutical composition. Dated this the 12th...

ABSTRACT Present invention provides novel process of preparing Netarsudil and pharmaceutically acceptable salts thereof and more specifically the present invention further provides compound of Formula II or pharmaceutically acceptable salts thereof, which act as intermediates for the preparation of Netarsudil a...

A PARENTERAL PHARMACEUTICAL COMPOSITION OF DYDROGESTERONE ABSTRACT The present invention relates to a parenteral pharmaceutical composition comprising therapeutically effective amount of dydrogesterone, and one or more pharmaceutically acceptable excipients. Further, the present invention also relates to the p...

The present invention relates to a stable ready-to-use parenteral composition comprising therapeutically effective amount of phenylephrine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. Dated this the 10th day of May 2024. ...

The present invention relates to stable and bioavailable pharmaceutical formulations useful for the oral administration comprising Semaglutide and one or more permeation enhancers, and process for their preparation. Oral administration of the formulations of the present invention can be used for the treatment of...

The present invention provides a synergistic pharmaceutical combination comprising a topical composition comprising Euphorbia Prostrata and an oral composition comprising Euphorbia Prostrata, wherein said topical and oral compositions comprises one or more pharmaceutical acceptable excipients and optionally one...

ABSTRACT The present invention provides a pharmaceutical combination comprising a Euphorbia Prostrata and Ispaghula husk. The combination and compositions of present invention are suitable for the treatment of piles, haemorrhoids, haemorrhoids during pregnancy, anal fissures, and/or anal fistula. Dated ...

ABSTRACT The present invention provides a topical composition of Euphorbia Prostrata, optionally comprising one or more pharmaceutically active agent, wherein said composition is suitable for the treatment of haemorrhoids, haemorrhoids during pregnancy, anal fissures, anal fistula, and varicose veins. ...

Present invention provides improved process for the preparation of Sitagliptin or its pharmaceutically acceptable salt. Present invention relates to a process for the preparation of Sitagliptin Phosphate using novel intermediate of Formula II.

PHARMACEUTICAL COMPOSITION COMPRISING PURE EXTRACT OF EUPHORBIA PROSTRATA ABSTRACT The present invention provides a pharmaceutical composition comprising pure extract of Euphorbia Prostrata substantially free of heavy metals and microbial contamination, wherein said extract has a controlled particle size and t...

The Present invention provides novel compound of Formula II or pharmaceutically acceptable salts thereof, which act as intermediates for the preparation of Abrocitinib and pharmaceutically acceptable salts thereof. Formula II The Present invention further provides process for the preparation novel compoun...

IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS OF DYDROGESTERONE AND A KIT THEREOF ABSTRACT The present invention relates to an immediate release pharmaceutical composition comprising dydrogesterone or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients. ...

The present invention relates to an improved process for the preparation of Rocuronium Bromide. The invention further relates to an improved process for the preparation of Rocuronium Bromide free of residual solvents; diacetyl impurity; des-pyrrolidine keto impurity as well as other impurities, ...

ABSTRACT The present invention relates to an improved process for preparation of Rosuvastatin or its pharmaceutical acceptable salt. The present invention further provides an improved process for the preparation of Rosuvastatin calcium by using compound of Formula I and III. ...

ABSTRACT Present invention provides process for the preparation of Latanoprostene Bunod using compound of Formula III or V. Formula III, wherein P is H or amine protecting group and X is a halogen. Dated 10th Day of Mar, 2023 For Mankind Pharma Ltd. ...

ABSTRACT Present invention provides process for the preparation of Latanoprostene Bunod and intermediate thereof. Present invention further provides process of purification of Latanoprostene Bunod and intermediate thereof. Dated 26th Day of Feb, 2024 For Mankind Pharma Ltd. ...

A STABLE OPHTHALMIC COMPOSITION OF PHENYLEPHRINE ABSTRACT The present invention relates to a stable ophthalmic composition comprising therapeutically effective amount of phenylephrine or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. The present invention furt...

PHARMACEUTICAL COMPOSITION OF LIFITEGRAST ABSTRACT The present invention provides a stable pharmaceutical composition comprising lifitegrast and one or more pharmaceutical excipients, wherein the pharmaceutical composition is free of antioxidant and/or preservative. It further relates to a method of preparing such...

ABSTRACT The invention relates to a stable pharmaceutical composition comprising levothyroxine or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients. The present invention further provides a stable pharmaceutical composition comprising about 325 mcg to abou...

The present invention relates to an ophthalmic composition comprising netarsudil or pharmaceutically acceptable salts thereof; bimatoprost or pharmaceutically acceptable salts thereof and one or more pharmaceutical acceptable excipients. It further relates to a method of preparing such compositions and use t...

The Present invention provides stable amorphous form, solid dispersion of Fezolinetant of Formula I and their process of preparation. Present invention further provides novel crystalline forms of Fezolinetant and their process of preparation. Dated 14th Day of August, 2024 For Mankind Pha...

The present invention provides an amorphous form of Resmetirom, method for its preparation. This invention also provides amorphous solid dispersion and premix of Resmetirom. The present invention also provides pharmaceutical compositions containing the same. Dated 28th Day of August, 2024 For Ma...

The present invention relates to a parenteral pharmaceutical composition comprising a therapeutically effective amount of Dydrogesterone or its pharmaceutically acceptable salt, and one or more pharmaceutically acceptable excipients. The present invention further provides a parenteral pharmaceutical composit...

The present invention relates to the pharmaceutical composition comprising dydrogesterone or ester (s) thereof in combination with aromatase inhibitor or salts thereof and one or more pharmaceutically acceptable excipients for the treatment or prevention of uterine disorders preferably uterine fibroids, aden...

Present invention provides novel process for the preparation of Abrocitinib compound of Formula I or its pharmaceutically acceptable salts thereof. Present invention provides novel compound of Formula II or pharmaceutically acceptable salts thereof, which act as intermediates for the preparation of Abroc...

The present invention relates to a pharmaceutical combination comprises of dydrogesterone or its ester (s), anthelmintic agent, wherein the said pharmaceutical combination is used for the treatment of uterine disorders preferably uterine fibroids, adenomyosis, endometriosis, heavy menstrual bleeding, or pain...

Present invention provides novel salts of Mavacamten compound of Formula I, Present invention further provides process for the preparation of novel salts of Mavacamten compound of Formula I. Dated 11th Day of Sept, 2024 For Mankind Pharma Ltd. ...

The present invention relates to a vaginal tablet for insertion into vagina comprising dydrogesterone or pharmaceutically acceptable salts or esters thereof, along with one or more pharmaceutically acceptable excipients. Dated this, 25th Day of September, 2024 ...

The present invention relates to a pharmaceutical combination comprises of Tyrosine kinase inhibitor, and HMG-CoA reductase inhibitor or antiprotozoal drug for the treatment of cancer. Further, the present invention also relates to a pharmaceutical composition comprising Tyrosine kinase inhibitor, HMG-CoA re...